Astellas Pharma Inc. and Pantherna Therapeutics GmbH announced that the companies have entered into a new technology evaluation agreement for research to generate mRNA-based regenerative medicine programmes using direct reprogramming (transdifferentiation).
This agreement expands the scope of the technology evaluation agreement for research, which Astellas and Pantherna entered into in 2021, to include new target organ.
Pantherna owns a proprietary platform of state-of-the-art, unique mRNA molecules (PTXmRNAs) for enhancing the efficiency of mRNA actions in the body. Under the new agreement, Pantherna
